Cencora, Inc. (NYSE:COR – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the sixteen ratings firms that are covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and thirteen have issued a buy recommendation on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $381.00.
Several research firms have recently commented on COR. Evercore restated an “outperform” rating and set a $350.00 price target (up from $330.00) on shares of Cencora in a research note on Thursday, August 6th. Weiss Ratings raised Cencora from a “buy (b-)” rating to a “buy (b)” rating in a report on Tuesday, October 6th. JPMorgan Chase & Co. lifted their price objective on shares of Cencora from $390.00 to $413.00 and gave the company an “overweight” rating in a research report on Tuesday, November 10th. Royal Bank Of Canada reissued a “sector perform” rating and issued a $330.00 price objective on shares of Cencora in a research note on Tuesday, September 8th. Finally, Wells Fargo & Company boosted their price objective on shares of Cencora from $395.00 to $400.00 and gave the company an “overweight” rating in a research note on Tuesday.
Check Out Our Latest Analysis on Cencora
Cencora Stock Down 2.1%
Cencora (NYSE:COR – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported $4.66 earnings per share for the quarter, topping analysts’ consensus estimates of $4.58 by $0.08. Cencora had a return on equity of 110.72% and a net margin of 1.03%. The company had revenue of $88.35 billion during the quarter, compared to analysts’ expectations of $87.95 billion. During the same period last year, the firm earned $3.84 EPS. The firm’s revenue for the quarter was up 5.5% on a year-over-year basis. As a group, research analysts anticipate that Cencora will post 19.58 EPS for the current year.
Cencora Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Monday, November 30th. Stockholders of record on Friday, November 13th will be paid a $0.66 dividend. This is a boost from Cencora’s previous quarterly dividend of $0.60. The ex-dividend date is Friday, November 13th. This represents a $2.64 annualized dividend and a dividend yield of 0.8%. Cencora’s dividend payout ratio (DPR) is 14.73%.
Insider Buying and Selling at Cencora
In other news, EVP Elizabeth Campbell sold 11,300 shares of the business’s stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $324.12, for a total transaction of $3,662,556.00. Following the transaction, the executive vice president directly owned 19,455 shares in the company, valued at $6,305,754.60. The trade was a 36.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.38% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Cencora
A number of hedge funds have recently added to or reduced their stakes in COR. BlackRock Inc. purchased a new stake in Cencora in the 2nd quarter valued at approximately $5,154,136,000. Boston Partners increased its position in Cencora by 7.8% during the 3rd quarter. Boston Partners now owns 5,247,872 shares of the company’s stock worth $1,578,543,000 after purchasing an additional 379,090 shares during the period. Bank of America Corp DE increased its position in Cencora by 6.9% during the 1st quarter. Bank of America Corp DE now owns 4,138,388 shares of the company’s stock worth $1,300,033,000 after purchasing an additional 267,318 shares during the period. Amundi raised its stake in shares of Cencora by 43.5% during the 2nd quarter. Amundi now owns 2,229,326 shares of the company’s stock worth $630,855,000 after buying an additional 676,066 shares in the last quarter. Finally, Carmignac Gestion raised its stake in shares of Cencora by 58.7% during the 2nd quarter. Carmignac Gestion now owns 1,747,363 shares of the company’s stock worth $494,463,000 after buying an additional 646,112 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.
Cencora Company Profile
Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical services company that connects pharmaceutical manufacturers with healthcare providers. Its core business includes sourcing and distributing medicines and other healthcare products to pharmacies, hospitals, health systems and other care providers. The company also provides services supporting specialty pharmaceuticals, including logistics, consulting and solutions for manufacturers and healthcare organizations. These services help manage the handling and delivery of complex medicines and support access to treatments.
See Also
- Five stocks we like better than Cencora
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.
